Identifying Missed Opportunities for Human Immunodeficiency Virus Pre-exposure Prophylaxis During Preventive Care and Reproductive Visits in Adolescents in the Deep South
Overview
Affiliations
Background: Pre-exposure prophylaxis (PrEP) for individuals at significant risk for Human Immunodeficiency Virus acquisition is approved for individuals weighing at least 35 kg by the Food and Drug Administration. This cross-sectional study analyzed indications for PrEP in a clinical setting.
Methods: There were 429 charts reviewed from adolescents between 15 and 21 years old seen for preventive care visits at an adolescent primary care center in the Deep South during a 1-year timeframe. Univariate and multivariable regression analyses were completed to identify factors associated with indications for PrEP.
Results: Forty-four percent of 429 adolescents (between 15 and 21 years) had a PrEP indication; 77% were women and 95% heterosexual. Significant factors associated with an indication for PrEP included living with a nonparent or nonrelative and polysubstance use. No adolescents with an indication for PrEP were prescribed PrEP. A sensitivity analysis comparing indications for PrEP between the 2014 and 2017 The Centers for Disease Control and Prevention Guidelines revealed no significant differences in percent with an indication (44.5% vs. 42.8%) or factors associated with indications.
Conclusions: Pre-exposure prophylaxis as a biomedical tool for adolescents and young adults (AYAs) may remain underutilized. A key factor in improving utilization involves providers being able to recognize AYAs who may have an indication for PrEP with a specific focus on those AYAs who do not live in households with parents or a surrogate family member and those who are polysubstance users.
Swendeman D, Rotheram-Borus M, Arnold E, Fernandez M, Comulada W, Ishimoto K AIDS Behav. 2024; 29(2):626-641.
PMID: 39604777 PMC: 11813953. DOI: 10.1007/s10461-024-04545-2.
Hill S, Pratt M, Elopre L, Simpson T, Gaines Lanzi R, Matthews L Sex Transm Dis. 2024; 51(7):466-471.
PMID: 38597652 PMC: 11182704. DOI: 10.1097/OLQ.0000000000001972.
Watson D, Listerud L, Drab R, Lin W, Momplaisir F, Bauermeister J J Int AIDS Soc. 2024; 27(2):e26211.
PMID: 38332521 PMC: 10853582. DOI: 10.1002/jia2.26211.
Isehunwa O, Hill S, Menninger A, Hubner B, Krakower D, Long D JMIR Res Protoc. 2023; 12:e44908.
PMID: 36943364 PMC: 10131664. DOI: 10.2196/44908.
Pratt M, Hill S, Elopre L, Simpson T, Lanzi R, Matthews L J Int Assoc Provid AIDS Care. 2022; 21:23259582221127936.
PMID: 36147031 PMC: 9511308. DOI: 10.1177/23259582221127936.